The Cell & Gene Catalyst (the Catalyst) profiled the opportunities present in the Australian cell and gene ecosystem this week during BioKorea 2024.
The presentation builds on previous AusBiotech showcases in Korea, providing an overview of the ecosystem and outlining the Catalyst’s national strategy. Delivered by Dr Marguerite Evans-Galea AM, Catalyst Director, it contributed to the “Partnering for successful regenerative medicine projects in Australia” session being hosted by MTPConnect and Austrade prior to BioKorea 2024.
The burgeoning field of cell and gene therapies offers significant potential and optimism, with many experts touting these therapies as the most critical discoveries of the future. The presentation presented the opportunities within the Australian industry, and informed international stakeholders on how to partner with Australian organisations across the value chain to develop advanced therapeutics.
The Catalyst is a national joint venture established and co-led by AusBiotech and Medicines Australia which aims to position Australia as a global leader in this field and to drive economic growth in the sector. To accelerate the development and commercialisation of cell and gene therapies in Australia, the Catalyst has a focus on strengthening the Australian ecosystem, with a particular emphasis on building the country’s capabilities across the entire value chain.
Held from 8-10 May in Seoul, BioKorea 2024 is Asia’s premier life science conference. AusBiotech is proud to support the Australian Trade and Investment Commission’s (Austrade) BioKorea 2024 delegation to strengthen ties with international markets, and highlight investment opportunities in Australia and our national life science capabilities.
The Australian presence is strong, with industry representation from across all five major states. AusBiotech’s support of BioKorea 2024’s Australian delegation is part of its global strategy to facilitate international opportunities for investment, collaborations and partnerships, with a focus on the markets important to members, including growth markets.
AusBiotech is committed to supporting these ongoing opportunities for industry, which are crucial for the growth of the Australian life sciences sector, and ultimately for continuing Australia’s position in the sector globally.
The organiser of BioKorea, the Korea Health Industry Development Institute (KHIDI), has led large Korean delegations to AusBiotech for several years, demonstrating the strong interest Korean companies have in collaborating with Australia’s biotech industry.
This year marks the 10-year anniversary of the AusBiotech-KHIDI partnership.
